Novartis Reports Three-Year EXPAND Data for Mayzent in Secondary Progressive MS

Novartis today presented three-year follow-up data from the Phase 3 EXPAND trial evaluating Mayzent (siponimod) in patients with secondary progressive multiple sclerosis. The data showed that Mayzent maintained significant reductions in disability progression over three years of treatment, with a 21% reduction in the risk of confirmed disability progression compared to placebo.